Genetic susceptibility to thalidomide embryopathy in humans: Study of candidate development genes
Thalidomide is a drug used worldwide for several indications, but the molecular mechanisms of its teratogenic property are not fully understood. Studies in animal models suggest the oxidative stress, the inhibition of angiogenesis, and the binding to E3‐ubiquitin ligase complex as mechanisms by whic...
Gespeichert in:
| Veröffentlicht in: | Birth defects research 2018-03, Vol.110 (5), p.456-461 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 461 |
|---|---|
| container_issue | 5 |
| container_start_page | 456 |
| container_title | Birth defects research |
| container_volume | 110 |
| creator | Gomes, Julia do Amaral Kowalski, Thayne Woycinck Fraga, Lucas Rosa Tovo‐Rodrigues, Luciana Sanseverino, Maria Teresa Vieira Schuler‐Faccini, Lavínia Vianna, Fernanda Sales Luiz |
| description | Thalidomide is a drug used worldwide for several indications, but the molecular mechanisms of its teratogenic property are not fully understood. Studies in animal models suggest the oxidative stress, the inhibition of angiogenesis, and the binding to E3‐ubiquitin ligase complex as mechanisms by which thalidomide can change the expression of genes important to embryonic development. In this study, seven polymorphisms in genes related to development (FGF8, FGF10, BMP4, SHH, TP53, TP63, and TP73) were analyzed in people with thalidomide embryopathy (TE) and compared to people without malformations. The sample consisted of 36 people with TE and 135 unrelated and nonsyndromic people who had their DNA genotyped by PCR real‐time. Although no allelic or genotypic differences were observed between the groups, we hypothesized that other regions in these genes and related genes may play an important role in thalidomide teratogenesis, which is known to have a genetic contribution. Identifying such molecular mechanisms is essential for the development of a molecule that will be analogue to thalidomide but safe enough to avoid the emergence of new cases of TE. |
| doi_str_mv | 10.1002/bdr2.1163 |
| format | Article |
| fullrecord | <record><control><sourceid>wiley_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1002_bdr2_1163</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>BDR21163</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3253-e91b96d954b9e9b7c1d3e5aa50581d5a4a5e08c32a92391538c7d8fea328e013</originalsourceid><addsrcrecordid>eNp1kLtOwzAYRi0EolXpwAsgrwxpfakbmw0KFKRKSNA98uUPNcpNsQPK25NSQCxM3zccneEgdE7JjBLC5sa1bEbpkh-hMVukLKEpS4___BGahvBGCKGS0ZTLUzRiiiquCB8jvYYKorc4dMFCE73xhY89jjWOO114V5feAYbStH3d6Ljrsa_writ1Fa7wS-xcj-scW10573QE7OAdiropoYr4dXCHM3SS6yLA9HsnaHt_t109JJun9ePqepNYzgRPQFGjlk6JhVGgTGqp4yC0FkRI6oReaAFEDqxWjCsquLSpkzloziQQyifo8qC1bR1CC3nWtL7UbZ9Rku1DZftQ2T7UwF4c2KYzJbhf8ifLAMwPwIcvoP_flN3cPrMv5Se2rnNZ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Genetic susceptibility to thalidomide embryopathy in humans: Study of candidate development genes</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Gomes, Julia do Amaral ; Kowalski, Thayne Woycinck ; Fraga, Lucas Rosa ; Tovo‐Rodrigues, Luciana ; Sanseverino, Maria Teresa Vieira ; Schuler‐Faccini, Lavínia ; Vianna, Fernanda Sales Luiz</creator><creatorcontrib>Gomes, Julia do Amaral ; Kowalski, Thayne Woycinck ; Fraga, Lucas Rosa ; Tovo‐Rodrigues, Luciana ; Sanseverino, Maria Teresa Vieira ; Schuler‐Faccini, Lavínia ; Vianna, Fernanda Sales Luiz</creatorcontrib><description>Thalidomide is a drug used worldwide for several indications, but the molecular mechanisms of its teratogenic property are not fully understood. Studies in animal models suggest the oxidative stress, the inhibition of angiogenesis, and the binding to E3‐ubiquitin ligase complex as mechanisms by which thalidomide can change the expression of genes important to embryonic development. In this study, seven polymorphisms in genes related to development (FGF8, FGF10, BMP4, SHH, TP53, TP63, and TP73) were analyzed in people with thalidomide embryopathy (TE) and compared to people without malformations. The sample consisted of 36 people with TE and 135 unrelated and nonsyndromic people who had their DNA genotyped by PCR real‐time. Although no allelic or genotypic differences were observed between the groups, we hypothesized that other regions in these genes and related genes may play an important role in thalidomide teratogenesis, which is known to have a genetic contribution. Identifying such molecular mechanisms is essential for the development of a molecule that will be analogue to thalidomide but safe enough to avoid the emergence of new cases of TE.</description><identifier>ISSN: 2472-1727</identifier><identifier>EISSN: 2472-1727</identifier><identifier>DOI: 10.1002/bdr2.1163</identifier><identifier>PMID: 29193903</identifier><language>eng</language><publisher>United States</publisher><subject>birth defects ; genetics ; limb reduction defects ; polymorphism ; teratogenesis</subject><ispartof>Birth defects research, 2018-03, Vol.110 (5), p.456-461</ispartof><rights>2017 Wiley Periodicals, Inc</rights><rights>2017 Wiley Periodicals, Inc.</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3253-e91b96d954b9e9b7c1d3e5aa50581d5a4a5e08c32a92391538c7d8fea328e013</citedby><cites>FETCH-LOGICAL-c3253-e91b96d954b9e9b7c1d3e5aa50581d5a4a5e08c32a92391538c7d8fea328e013</cites><orcidid>0000-0002-0674-0494 ; 0000-0002-8732-6059</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fbdr2.1163$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fbdr2.1163$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,777,781,1412,27905,27906,45555,45556</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29193903$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gomes, Julia do Amaral</creatorcontrib><creatorcontrib>Kowalski, Thayne Woycinck</creatorcontrib><creatorcontrib>Fraga, Lucas Rosa</creatorcontrib><creatorcontrib>Tovo‐Rodrigues, Luciana</creatorcontrib><creatorcontrib>Sanseverino, Maria Teresa Vieira</creatorcontrib><creatorcontrib>Schuler‐Faccini, Lavínia</creatorcontrib><creatorcontrib>Vianna, Fernanda Sales Luiz</creatorcontrib><title>Genetic susceptibility to thalidomide embryopathy in humans: Study of candidate development genes</title><title>Birth defects research</title><addtitle>Birth Defects Res</addtitle><description>Thalidomide is a drug used worldwide for several indications, but the molecular mechanisms of its teratogenic property are not fully understood. Studies in animal models suggest the oxidative stress, the inhibition of angiogenesis, and the binding to E3‐ubiquitin ligase complex as mechanisms by which thalidomide can change the expression of genes important to embryonic development. In this study, seven polymorphisms in genes related to development (FGF8, FGF10, BMP4, SHH, TP53, TP63, and TP73) were analyzed in people with thalidomide embryopathy (TE) and compared to people without malformations. The sample consisted of 36 people with TE and 135 unrelated and nonsyndromic people who had their DNA genotyped by PCR real‐time. Although no allelic or genotypic differences were observed between the groups, we hypothesized that other regions in these genes and related genes may play an important role in thalidomide teratogenesis, which is known to have a genetic contribution. Identifying such molecular mechanisms is essential for the development of a molecule that will be analogue to thalidomide but safe enough to avoid the emergence of new cases of TE.</description><subject>birth defects</subject><subject>genetics</subject><subject>limb reduction defects</subject><subject>polymorphism</subject><subject>teratogenesis</subject><issn>2472-1727</issn><issn>2472-1727</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp1kLtOwzAYRi0EolXpwAsgrwxpfakbmw0KFKRKSNA98uUPNcpNsQPK25NSQCxM3zccneEgdE7JjBLC5sa1bEbpkh-hMVukLKEpS4___BGahvBGCKGS0ZTLUzRiiiquCB8jvYYKorc4dMFCE73xhY89jjWOO114V5feAYbStH3d6Ljrsa_writ1Fa7wS-xcj-scW10573QE7OAdiropoYr4dXCHM3SS6yLA9HsnaHt_t109JJun9ePqepNYzgRPQFGjlk6JhVGgTGqp4yC0FkRI6oReaAFEDqxWjCsquLSpkzloziQQyifo8qC1bR1CC3nWtL7UbZ9Rku1DZftQ2T7UwF4c2KYzJbhf8ifLAMwPwIcvoP_flN3cPrMv5Se2rnNZ</recordid><startdate>20180315</startdate><enddate>20180315</enddate><creator>Gomes, Julia do Amaral</creator><creator>Kowalski, Thayne Woycinck</creator><creator>Fraga, Lucas Rosa</creator><creator>Tovo‐Rodrigues, Luciana</creator><creator>Sanseverino, Maria Teresa Vieira</creator><creator>Schuler‐Faccini, Lavínia</creator><creator>Vianna, Fernanda Sales Luiz</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0000-0002-0674-0494</orcidid><orcidid>https://orcid.org/0000-0002-8732-6059</orcidid></search><sort><creationdate>20180315</creationdate><title>Genetic susceptibility to thalidomide embryopathy in humans: Study of candidate development genes</title><author>Gomes, Julia do Amaral ; Kowalski, Thayne Woycinck ; Fraga, Lucas Rosa ; Tovo‐Rodrigues, Luciana ; Sanseverino, Maria Teresa Vieira ; Schuler‐Faccini, Lavínia ; Vianna, Fernanda Sales Luiz</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3253-e91b96d954b9e9b7c1d3e5aa50581d5a4a5e08c32a92391538c7d8fea328e013</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>birth defects</topic><topic>genetics</topic><topic>limb reduction defects</topic><topic>polymorphism</topic><topic>teratogenesis</topic><toplevel>online_resources</toplevel><creatorcontrib>Gomes, Julia do Amaral</creatorcontrib><creatorcontrib>Kowalski, Thayne Woycinck</creatorcontrib><creatorcontrib>Fraga, Lucas Rosa</creatorcontrib><creatorcontrib>Tovo‐Rodrigues, Luciana</creatorcontrib><creatorcontrib>Sanseverino, Maria Teresa Vieira</creatorcontrib><creatorcontrib>Schuler‐Faccini, Lavínia</creatorcontrib><creatorcontrib>Vianna, Fernanda Sales Luiz</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Birth defects research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gomes, Julia do Amaral</au><au>Kowalski, Thayne Woycinck</au><au>Fraga, Lucas Rosa</au><au>Tovo‐Rodrigues, Luciana</au><au>Sanseverino, Maria Teresa Vieira</au><au>Schuler‐Faccini, Lavínia</au><au>Vianna, Fernanda Sales Luiz</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Genetic susceptibility to thalidomide embryopathy in humans: Study of candidate development genes</atitle><jtitle>Birth defects research</jtitle><addtitle>Birth Defects Res</addtitle><date>2018-03-15</date><risdate>2018</risdate><volume>110</volume><issue>5</issue><spage>456</spage><epage>461</epage><pages>456-461</pages><issn>2472-1727</issn><eissn>2472-1727</eissn><abstract>Thalidomide is a drug used worldwide for several indications, but the molecular mechanisms of its teratogenic property are not fully understood. Studies in animal models suggest the oxidative stress, the inhibition of angiogenesis, and the binding to E3‐ubiquitin ligase complex as mechanisms by which thalidomide can change the expression of genes important to embryonic development. In this study, seven polymorphisms in genes related to development (FGF8, FGF10, BMP4, SHH, TP53, TP63, and TP73) were analyzed in people with thalidomide embryopathy (TE) and compared to people without malformations. The sample consisted of 36 people with TE and 135 unrelated and nonsyndromic people who had their DNA genotyped by PCR real‐time. Although no allelic or genotypic differences were observed between the groups, we hypothesized that other regions in these genes and related genes may play an important role in thalidomide teratogenesis, which is known to have a genetic contribution. Identifying such molecular mechanisms is essential for the development of a molecule that will be analogue to thalidomide but safe enough to avoid the emergence of new cases of TE.</abstract><cop>United States</cop><pmid>29193903</pmid><doi>10.1002/bdr2.1163</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-0674-0494</orcidid><orcidid>https://orcid.org/0000-0002-8732-6059</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2472-1727 |
| ispartof | Birth defects research, 2018-03, Vol.110 (5), p.456-461 |
| issn | 2472-1727 2472-1727 |
| language | eng |
| recordid | cdi_crossref_primary_10_1002_bdr2_1163 |
| source | Wiley Online Library Journals Frontfile Complete |
| subjects | birth defects genetics limb reduction defects polymorphism teratogenesis |
| title | Genetic susceptibility to thalidomide embryopathy in humans: Study of candidate development genes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T08%3A17%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Genetic%20susceptibility%20to%20thalidomide%20embryopathy%20in%20humans:%20Study%20of%20candidate%20development%20genes&rft.jtitle=Birth%20defects%20research&rft.au=Gomes,%20Julia%20do%20Amaral&rft.date=2018-03-15&rft.volume=110&rft.issue=5&rft.spage=456&rft.epage=461&rft.pages=456-461&rft.issn=2472-1727&rft.eissn=2472-1727&rft_id=info:doi/10.1002/bdr2.1163&rft_dat=%3Cwiley_cross%3EBDR21163%3C/wiley_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/29193903&rfr_iscdi=true |